Pharma BD Deal Intelligence
Phase 2 NK-REALM trial of haploidentical NK cells (K-NK002) to prevent post-transplant relapse in AML/MDS — status: Withdrawn.
Revamp pays off for Kiadis with $358M Sanofi buyout after company pivoted from failed lead product to proprietary NK-cell therapy platform
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Sanofi acquired Dutch clinical-stage biotech Kiadis Pharma in an all-cash tender offer (EUR 5.45/share, ~EUR 308M / ~$359M; ~272% premium) announced Nov 2, 2020 and completed April 16, 2021, to gain Kiadis's proprietary off-the-shelf (allogeneic) K-NK natural-killer cell therapy platform. The lead program K-NK002 was in a Phase 2 study (NK-REALM, NCT04395092) to prevent post-transplant relapse in AML/MDS. POST-CLOSE OUTCOME: the platform bet did not pan out — the NK-REALM Phase 2 trial was withdrawn and K-NK002 is listed as discontinued, and Sanofi subsequently wound down the acquired Kiadis NK-cell division as part of a broader pipeline reprioritization away from oncology toward immunology. Sanofi has since pursued NK-cell engagers via its separate Innate Pharma ANKET collaboration rather than the Kiadis cell-therapy platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kiadis Pharma NV (this deal) | 2020 | $359M | 41 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2020 deals · Sanofi SA deals · Gene Therapy deals